5 Big Drug Companies Face R&D Drought
Five of the world’s biggest drug companies do not have any potential billion-dollar drugs in late-stage development, highlighting the industry’s current poor R&D productivity, according to a report released on Wednesday.
Informatics Moves to the Head of the Class
The race is on to increase the quantity and quality of bio-IT training programs as government and academia bet the need will be great. Will the job market back that up?
Nanopharmaceuticals Open Up Brand New Field Of Study
Drug-binding molecules tiny enough to travel through the body’s smallest capillaries may provide a way to spare the heart and other organs from the toxic effects of drug overdose.
The pharmaceutical industry is experiencing a deepening productivity crisis. The industry’s preferred escape mechanism from this predicament has been to increase investment in current business activities – primarily R&D and sales – to sustain productivity levels or, ideally, to exploit economies of scale. This has been implemented through organic growth of critical resources and/or M&A. The fact that productivity continues to decline after a decade of vigorous growth in investment levels, and against a background of increasing company size, bears testament to the fallibility of this strategy.